Sebela Pharmaceuticals

Sebela Pharmaceuticals is a US-based company focused on developing innovative pharmaceutical products, particularly in Gastroenterology and Women's Health, offering effective treatments to enhance patient care. Established in 2013 in Roswell, US, Sebela Pharmaceuticals specializes in pharmaceutical development. The company emerged with a focus on addressing unmet medical needs without significant pivots in its strategic direction. The firm was formed through the collaboration of its management team and has successfully completed a total of 1 deal as of August 26, 2013.

Sebela Pharmaceuticals specializes in developing innovative pharmaceutical products, primarily focusing on Gastroenterology and Women's Health. The company’s core offerings include Tegoprazan, designed for the treatment of gastroesophageal reflux disease (GERD). This product provides effective acid suppression, contributing to improved quality of life for patients. Additionally, through its affiliate, Braintree, Sebela addresses gastrointestinal diseases with a range of therapeutic options.

The company targets healthcare providers, hospitals, and clinics in the United States and selected international markets, ensuring its products reach a broad customer base that includes both patients and healthcare professionals. Sebela Pharmaceuticals generates revenue through its sales of prescription pharmaceuticals, particularly focused on its flagship product, Tegoprazan. Transactions occur directly between the company and healthcare providers, as well as through partnerships with wholesalers and distributors that facilitate broader market access. Revenue is derived from the sale of these prescription medications, with structured pricing plans designed to accommodate various healthcare reimbursement models.

The company operates on a B2B model where healthcare providers prescribe products to patients, ensuring a consistent revenue stream tied to prescription volumes and market demand. Sebela Pharmaceuticals is focused on expanding its product line and is currently in the process of developing new medications for gastrointestinal disorders, with plans for potential launches in the coming years. The company aims to broaden its market presence in additional international regions, targeting expansion into Europe and Asia by 2025. The recent funding round, concluded in August 2013 with an investment from DFW Capital and Altiva Capital alongside management, will support these growth initiatives, although financial terms were not disclosed.